|
Federal
Register Notices > Manufacturers
2009 > Mallinckrodt Inc
FR Doc E9-1054[Federal Register: January 21, 2009 (Volume 74, Number 12)]
[Notices] [Page 3643] From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr21ja09-127]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec.
1301.33(a) of Title 21 of the Code of Federal Regulations (CFR),
this is notice that on November 18, 2008, Mallinckrodt Inc., 3600 North Second
Street, St. Louis, Missouri 63147, made application by renewal to the Drug
Enforcement Administration (DEA) to be registered as a bulk manufacturer of the
basic classes of controlled substances listed in schedule I and II:
|
Drug
|
Schedule
|
|
Tetrahydrocannabinols (7370)
|
I
|
|
Codeine-N-oxide (9053)
|
I
|
|
Dihydromorphine (9145)
|
I
|
|
Difenoxin (9168)
|
I
|
|
Morphine-N-oxide (9307)
|
I
|
|
Normorphine (9313)
|
I
|
|
Norlevorphanol (9634)
|
I
|
|
Amphetamine (1100)
|
II
|
|
Methamphetamine (1105)
|
II
|
|
Methylphenidate (1724)
|
II
|
|
Nabilone (7379)
|
II
|
|
Codeine (9050)
|
II
|
|
Diprenorphine (9058)
|
II
|
|
Etorphine HCL (9059)
|
II
|
|
Dihydrocodeine (9120)
|
II
|
|
Oxycodone (9143)
|
II
|
|
Hydromorphone (9150)
|
II
|
|
Diphenoxylate (9170)
|
II
|
|
Ecgonine (9180)
|
II
|
|
Hydrocodone (9193)
|
II
|
|
Levorphanol (9220)
|
II
|
|
Meperidine (9230)
|
II
|
|
Methadone (9250)
|
II
|
|
Methadone intermediate (9254)
|
II
|
|
Metopon (9260)
|
II
|
|
Dextropropoxyphene, bulk (9273)
|
II
|
|
Morphine (9300)
|
II
|
|
Oripavine (9330)
|
II
|
|
Thebaine (9333)
|
II
|
|
Opium extracts (9610)
|
II
|
|
Opium fluid extract (9620)
|
II
|
|
Opium tincture (9630)
|
II
|
|
Opium, powdered (9639)
|
II
|
|
Opium, granulated (9640)
|
II
|
|
Levo-alphacetylmethadol (9648)
|
II
|
|
Oxymorphone (9652)
|
II
|
|
Noroxymorphone (9668)
|
II
|
|
Alfentanil (9737)
|
II
|
|
Remifentanil (9739)
|
II
|
|
Sufentanil (9740)
|
II
|
|
Fentanyl (9801)
|
II
|
The firm plans to manufacture the listed controlled substances for internal
use and for sale to other companies.
Any other such applicant, and any person who is presently registered with DEA
to manufacture such substances, may file comments or objections to the issuance
of the proposed registration pursuant to 21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in quintuplicate,
to the Drug Enforcement Administration, Office of Diversion Control, Federal
Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia
22152; and must be filed no later than March 23, 2009.
Dated: January 9, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration.
[FR Doc. E9-1054 Filed 1-16-09; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
|
